Advancing Vaccines in the Genomics Era

Organizer(s): Bali Pulendran, Chris Wilson and Rino Rappuoli

Sponsored by FAPERJ – Rio de Janeiro State Agency for Research Development. Part of the Keystone Symposia Global Health Series, supported by the Bill & Melinda Gates Foundation.

For important information on the coronavirus, please click here

Summary of Meeting:

A direct consequence of the Human Genome Project has been the development of so-called “omic” technologies (e.g. genomics, proteomics) that can be used to probe the molecular networks that control biological systems. Such technologies are beginning to be applied to vaccinology to obtain deeper insights about the molecular networks that orchestrate protective immunity induced by vaccination in humans. Such systems biological approaches are enhancing our understanding of the correlates of protective immunities, of the early innate immune signatures of vaccine efficacy, and guiding the rational design of novel and safer vaccines and adjuvants. This meeting will explore the potential of systems biology in vaccine design and development. Participants will include vaccinologists, immunologists, virologists, microbiologists, scientists using systems approaches in other areas of biomedical research, as well as individuals working in industry and health policy who are interested in the potential of genomics in vaccinology. The meeting will address how systems biology has provided insight into the immune response to vaccines, and will also discuss the technical and bioinformatic challenges associated with using systems biology approaches. Researchers will show 'systems vaccinology' approaches can be implemented in vaccine development and clinical trial monitoring.

Global Health Travel Award Deadline: June 4 2013

Scholarship Deadline: June 27 2013

Discounted Abstract Deadline: June 27 2013

Abstract Deadline: July 30 2013

Discounted Registration Deadline: August 29 2013

Abstacts when book is in proofing process

Keystone Symposia thanks our Sponsor(s) for generously supporting this meeting:

We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:

Dynavax Technologies Corporation

Novartis Vaccines and Diagnostics

We gratefully acknowledge the generous grant for this conference provided by:

National Institute of Allergy and Infectious Diseases (NIAID)
Grant No. 1R13AI108157-01
The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:

Click here to view more of these organizations

Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:

Click here to view more of these organizations